On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

These protease inhibitors were discovered using the company’s proprietary structure-based drug discovery technology and advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.